Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Orient Pharma Co's share price for the quarter that ended in Dec. 2025 was NT$26.15. Orient Pharma Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 243 Mil. Therefore, Orient Pharma Co's market cap for the quarter that ended in Dec. 2025 was NT$6,355 Mil.
Orient Pharma Co's quarterly market cap
declined
from Jun. 2025 (NT$8,208 Mil) to Sep. 2025 (NT$6,210 Mil) but then
increased
from Sep. 2025 (NT$6,210 Mil) to Dec. 2025 (NT$6,355 Mil).
Orient Pharma Co's annual market cap
increased
from Dec. 2023 (NT$4,427 Mil) to Dec. 2024 (NT$8,007 Mil) but then
declined
from Dec. 2024 (NT$8,007 Mil) to Dec. 2025 (NT$6,355 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Orient Pharma Co's Enterprise Value for Today is NT$6,179 Mil.
Orient Pharma Co (ROCO:4166) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Orient Pharma Co Market Cap Related Terms
Orient Pharma Co Market Cap Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Orient Pharma Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Market Cap of NT$6,611 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orient Pharma Co and its competitors. According to the industry distribution chart, Orient Pharma Co ranks #530 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is Orient Pharma Co's Market Cap too high?
Orient Pharma Co's current Market Cap is NT$6,611 Mil. Based on the distribution chart, Orient Pharma Co ranks #530 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #530 out of 1024 companies for Market Cap. This places Orient Pharma Co in the lower half of its industry. The industry median Market Cap is 220.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 220.02, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 220.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Market Cap is NT$6,611 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Market Cap is NT$6,611 Mil. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Market Cap is NT$6,611 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Market Cap: NT$6,611 Mil
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
